Document is current
Any future updates will be listed below
-
Authors
Rubino, Francesco
Brown, Wendy A.
Schauer, Philip R.
Pattou, Francois
Cohen, Ricardo V.
-
Funding
Funding for this research was provided by:
No funding source for this submission
- License Information
-
More Information
Article History
Received: 23 July 2025
Revised: 5 August 2025
Accepted: 6 August 2025
First Online: 13 August 2025
Declarations
:
: FR reports research grants from Ethicon (Johnson & Johnson), Novo Nordisk and Medtronic; Speaking honoraria from Medtronic, Ethicon, Novo Nordisk, Eli Lilly, Amgen, Astra Zeneca. FR is also member of Data and Safety Monitoring Board(DSMB)for GI Metabolic Solution Inc and President of Metabolic Health Institute (non-profit).WAB reports: Grants from Johnson and Johnson, Medtronic, GORE, Applied Medical, Novo Nordisc, NHMRC, Myerton and the Australian Commonwealth Government. Personal fees from Johnson and Johnson, GORE, Novo Nordisc, Pfizer, Medtronic, Lily and Merck Sharpe and Dohme for lectures and advisory boards.Philip R. Schauer reports receiving research grants from the National Institutes of Health, Ethicon and Medtronic; receiving personal consulting fees or honoraria from GI Dynamics; Keyron; Mediflix, Metabolic Health International, LTD, Heron, Novo Nordisk, Klens; serving on scientific advisory boards for SE Healthcare Board of Directors; Lilly, GI Dynamics ; Keyron; Regeneron; Mediflix, and having ownership interest in SE Healthcare LLC, Mediflix, Metabolic Health International, LTD. FP reports payed lectures and fees from Lilly, Novo Nordisk, Medtronic and Ethicon. RVC received grants from Johnson & Johnson and Medtronic (paid to institution); consulting fees from Regeneron; honoraria from Johnson & Johnson, Medtronic, Novo Nordisk, Merck, and Boston Scientific; participated on scientific advisory boards for Johnson & Johnson, Morphic Medical, and Medtronic.
Free to read: This content has been made available to all.
